Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,641 INR
Change Today -23.50 / -1.41%
Volume 1.4M
LPC On Other Exchanges
Symbol
Exchange
OTC US
As of 7:06 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

lupin ltd (LPC) Snapshot

Open
1,670
Previous Close
1,664
Day High
1,675
Day Low
1,634
52 Week High
04/8/15 - 2,115
52 Week Low
08/8/14 - 1,107
Market Cap
738.1B
Average Volume 10 Days
2.5M
EPS TTM
53.54
Shares Outstanding
449.9M
EX-Date
07/14/15
P/E TM
30.6x
Dividend
7.50
Dividend Yield
0.46%
Current Stock Chart for LUPIN LTD (LPC)

Related News

No related news articles were found.

lupin ltd (LPC) Related Businessweek News

No Related Businessweek News Found

lupin ltd (LPC) Details

Lupin Limited, a pharmaceutical company, produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), gastro-intestinal, anti-diabetic, anti-infective, NSAID, anti- tuberculosis, cephalosporin, gynaecology, and other therapeutic areas; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, cardiovascular, CNS, analgesics, and anti-gout. The company also develops drug delivery technologies; and creates and develops biosimilars for various therapeutic indications, such as oncology, inflammation, antivirals, osteoporosis, rheumatoid arthritis, and ophthalmics. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, infections, and metabolic/endocrine disorders. Lupin Limited has a strategic licensing agreement with InspiRX Inc. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

15,000 Employees
Last Reported Date: 06/27/15
Founded in 1968

lupin ltd (LPC) Top Compensated Officers

Founder, Chairman, Chairman of Allotment Comm...
Total Annual Compensation: 36.7M
Chief Financial Officer and Member of Risk Ma...
Total Annual Compensation: 79.2M
Vice Chairman, Chairman of Share Transfer Com...
Total Annual Compensation: 139.4M
Managing Director, Executive Director, Member...
Total Annual Compensation: 81.5M
Executive Director, Member of Share Transfer ...
Total Annual Compensation: 4.6M
Compensation as of Fiscal Year 2015.

lupin ltd (LPC) Key Developments

Lupin Limited Approves Dividend for the Year Ended March 31, 2015

Lupin Limited at its AGM held on July 23, 2015, approved dividend at INR 7.50 per equity share for the year ended March 31, 2015.

Lupin Limited Announces Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2015

Lupin Limited announced unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2015. Net sales stood at INR 30,743 million during the first quarter of 2016 as compared to INR 32,840 million, in the first quarter of 2015. Earnings before interest, tax, depreciation and amortization (EBITDA) were INR 8,922 million during the first quarter of 2016 as compared to INR 11,437 million, in the first quarter of 2015. Profit before tax (PBT) was INR 7,891 million during the first quarter of 2016 as compared to INR 10,325 million, in the first quarter of 2015. Net profits stood at INR 5,250 million during the first quarter of 2016 as compared to INR 6,247 million, in the first quarter of 2015. Total revenue was INR 31,502 million against INR 33,408 million a year ago. EBIT was INR 7,915 million against INR 10,351 million a year ago. Capital Expenditure stood at INR 2,482 million during the quarter. Profit from operations before other income, finance costs and exceptional items was INR 7,159.4 million against INR 10,061.7 million a year ago. Profit from ordinary activities after tax was INR 5,247.3 million against INR 6,295.7 million a year ago. Diluted earnings per share were INR 11.60 against INR 13.87 a year ago. For the quarter, the standalone company reported net sales were INR 25,401.4 million against INR 29,556.4 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 8,549.2 million against INR 13,694.2 million a year ago. Profit from ordinary activities before tax was INR 9,338.5 million against INR 13,917.3 million a year ago. Profit from ordinary activities after tax was INR 6,999.2 million against INR 10,167.3 million a year ago. Diluted earnings per share were INR 15.47 against INR 22.57 a year ago.

Pharma Dynamics (Pty) Ltd. Announces Unaudited Sales Results for the First Quarter Ended June 30, 2015

Pharma Dynamics (Pty) Ltd. announced unaudited sales results for the first quarter ended June 30, 2015. The company achieved sales of INR 3,231 million in the first quarter of 2016 as compared to INR 3,415 million during first quarter of 2015. Kyowa sales (excluding Kyowa CritiCare) were INR 2,483 million for the first quarter of 2016 as compared to INR 2,640 million in the first quarter of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPC:IN 1,640.50 INR -23.50

LPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $70.25 USD -0.08
H Lundbeck A/S kr160.80 DKK +2.00
Ipca Laboratories Ltd 725.75 INR +4.15
Krka dd Novo mesto €64.03 EUR -0.59
Piramal Enterprises Ltd 905.15 INR +4.10
View Industry Companies
 

Industry Analysis

LPC

Industry Average

Valuation LPC Industry Range
Price/Earnings 32.0x
Price/Sales 5.8x
Price/Book 8.3x
Price/Cash Flow 26.9x
TEV/Sales 5.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LUPIN LTD, please visit www.lupinworld.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.